Our customers use our (cell) models because they represent a diversity of the disease that has been unattainable to date. It allows drug and cancer researchers to make better decisions about which populations of patients are more likely to respond effectively to drugs that are under investigation.
David Deems, CEO
Transforming the Search for Personalized Therapies
Cellaria Cell Models
Cellaria’s in vitro cancer cell models are derived directly from patient tumors to reflect the unique nature and complexity of each patient’s disease.
Our models are traceable back to initial patient tumor and clinical conditions, simplifying the analysis of patient-specific responses.
Cellaria Media
Our Renaissance Essential Tumor MediumTM utilizes a simple, feeder-free protocol for multiple solid tumor types including breast, lung, colon, and ovarian. Our WIT Culture Media are optimized for the expansion of normal human mammary epithelial cells and are completely defined and serum-free.
Control Products
Our RNA controls are derived from tumors that are relevant to your assay, while our DNA controls mirror the mutations that are measured in your assay.
Custom Services
Cancer Cell Model Development and Stem Cell Services
With Cellaria you have a dedicated, innovative partner in cancer and stem cell research. Draw on our deep industry expertise and patient-specific cancer and iPS cell models to seek out answers to critical questions and gain a technological edge.
From custom cancer cell model development to next-generation stem cell cell services, we provide highly specialized single source solutions to support your progress—every step of the way.
Latest Technical Resources
New research demonstrates the value of patient-specific cancer models in studies of metastasis and drug resistance.
Cellaria scientists to present latest studies at AACR 2021 At the annual meeting of the American Association for Cancer Research (AACR 2021: April...
Leading innovators collaborate to provide new, patient representative cell culture solutions for smarter in vitro research.
Cellaria Inc and BioLamina pool expertise to support better biological and drug research. 02/11/2021 WAKEFIELD, MA: One of the biggest challenges in...
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J.,...
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.